Ignite Creation Date:
2024-10-26 @ 3:41 PM
Last Modification Date:
2024-10-26 @ 3:41 PM
Study NCT ID:
NCT06624319
Status:
NOT_YET_RECRUITING
Last Update Posted:
None
First Post:
2024-09-28
Brief Title:
Two Doses of Dexmedetomidine as Adjuvent to Bupivacaine in Tap Block
Sponsor:
None
Organization:
None
Study Overview
Official Title:
Comparing the Analgesic Effect of Two Different Doses of Dexmedetomidine Added to Bupivacaine in Ultrasound-guided Transversus Abdominis Plane Block in Patients Undergoing Lower Abdominal Cancer Surgeries A Randomized Clinical Trial
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
Dexmedtap
Brief Summary:
The aim of this study to determine the optimal dose of dexmedetomidine as an adjuvant to bupivacaine in US guided TAP block for preemptive analgesia In patients undergoing lower abdominal cancer surgeries
Detailed Description:
The transversus abdominis plane TAP involves innervations of the anterolateral abdominal wall derived from T6-L1 The block can be given either by anatomical landmark technique or by using an ultrasound probe The local anesthetic is deposited in a plane between internal oblique and transversus abdominis muscle It provides adequate postoperative analgesia following various abdominal surgeriesDexmedetomidine is an alpha-2 agonist that has been approved as a venous sedative and an adjuvant for pain relief In previous studies the addition of dexmedetomidine to bupivacaine in the TAP block has prolonged the effect of this block So far the optimal dose of dexmedetomidine for the TAP block has not been determined
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None